“Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• “Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma (Articolo in rivista) (literal)

Anno

• 2011-01-01T00:00:00+01:00 (literal)

Alternative label

• Iurescia S.*, Fioretti D.*, Fazio V.M. and Rinaldi M. (*first co-authorship) (2011)
  “Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma
  in Current gene therapy (Print)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Iurescia S.*, Fioretti D.*, Fazio V.M. and Rinaldi M. (*first co-authorship) (literal)

Pagina inizio

• 414 (literal)

Pagina fine

• 422 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 11 (literal)

Rivista

• Current gene therapy (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

• 5 (literal)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Sandra Iurescia, Daniela Fioretti, Monica Rinaldi: Institute of Translational Pharmacology, Department of Medicine, National Research Council (CNR); Vito Michele Fazio Laboratory of Molecular Medicine and Biotechnology, CIR, University of Rome Campus Bio-medico (literal)

Titolo

• “Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma (literal)

Abstract

• Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a cancer vaccine. It has been theorized that effective cancer vaccines can be developed using the minimum essential subset of T cell and B cell epitopes that comprise the ‘immunome’, the universe of neoplasm-derived peptides that interface with B and T cells of the host immune system. Idiotypic antigenic determinants of a B-cell lymphoma lie within the hypervariable regions and mainly within the complementarity-determining regions (CDR)s 3. Thus, the CDR3s are considered a “hot spot” of particular interest for construction of subunit vaccines. DNA vaccines, whose safety and tolerability are substantiated in completed and ongoing clinical trials, have emerged as a novel lymphoma vaccine formulation for antigen-specific immunotherapy. The molecular precision tools offered by gene-based vaccines allow to explore the use of CDR3 sequence as an anti-lymphoma vaccine. (literal)

Prodotto di

• Sviluppo di strategie innovative di immunoterapia (ME.P03.015.003) (Modulo)

Autore CNR

• MONICA RINALDI (Unità di personale interno)
• DANIELA FIORETTI (Unità di personale interno)
• SANDRA IURESCIA (Persona)

Insieme di parole chiave

• Parole chiave di "“Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma" (Insieme di parole chiave)

Incoming links:

Autore CNR di

• MONICA RINALDI (Unità di personale interno)
• DANIELA FIORETTI (Unità di personale interno)
• SANDRA IURESCIA (Persona)

Prodotto

• Sviluppo di strategie innovative di immunoterapia (ME.P03.015.003) (Modulo)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Current gene therapy (Rivista)

Insieme di parole chiave di

• Parole chiave di "“Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma" (Insieme di parole chiave)